5:47 PM
 | 
Jan 06, 2009
 |  BC Extra  |  Clinical News

Kythera reports Phase II data for ATX-101

Kythera (Calabasas, Calif.) said ATX-101 injectable sodium deoxycholate met the primary endpoint of safety and the secondary endpoints measuring efficacy in a...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >